Linked Life Data

12950664

Source:http://linkedlifedata.com/resource/pubmed/id/12950664

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2003-9-2
pubmed:abstractText
We evaluated gametocyte carriage and intensities of gametocytaemia in 710 children presenting with acute, symptomatic, uncomplicated Plasmodium falciparum malaria who were treated with various antimalarial drug regimens: chloroquine (CQ); chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist that reverses CQ resistance in P. falciparum in vitro and in vivo (CQCP); chloroquine plus ketotifen, a histamine H1 receptor antagonist that reverses CQ resistance in P. falciparum in vitro but not in vivo in the present study (CQK); chloroquine plus pyrimethamine-sulphadoxine (CQPS); amodiaquine (AQ); amodiaquine plus pyrimethamine-sulphadoxine (AQPS); and pyrimethamine-sulphadoxine (PS). On presentation, gametocyte carriage was significantly higher in CQ-resistant (CQ-R) than in CQ-sensitive (CQ-S) infections. Following CQ treatment, gametocyte carriage was significantly higher at all times after treatment and gametocyte density significantly higher on day 7 of follow-up in children with CQ-R than CQ-S infections. CQ treatment of CQ-R infections resulted in significantly higher density of gametocytaemia on day 7 compared with pre-treatment (day 0), but similar treatment of CQ-S infections resulted in significantly lower density of gametocytaemia on day 14 compared with day 0. Among children with CQ-R infections, those with mild (RI) resistance carried gametocytes significantly more often than those with moderate (RII) resistance on days 5 and 7 of follow-up (P = 0.04 and 0.01, respectively). Disposition kinetics of gametocytaemia using a non-compartmental method showed that the half life of gametocytaemia was longer and the clearance slower in children with CQ-R than in those with CQ-S infections. PS treatment was associated with significantly higher gametocyte carriage at all times between days 1 and 14, and significantly higher gametocytaemias on days 7 and 14 than in the other treatment regimens. Combination of AQ with PS significantly decreased gametocyte carriage at all times between days 1 and 14 of follow-up. Continuing use of CQ in CQ-R infections may encourage transmission of CQ-R infections; SP monotherapy is associated with significant gametocyte carriage and gametocytaemia and may encourage transmission of SP resistant infections as resistance to the drug increases.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1360-2276
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
783-92
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12950664-Age Factors, pubmed-meshheading:12950664-Amodiaquine, pubmed-meshheading:12950664-Animals, pubmed-meshheading:12950664-Antimalarials, pubmed-meshheading:12950664-Child, pubmed-meshheading:12950664-Child, Preschool, pubmed-meshheading:12950664-Chloroquine, pubmed-meshheading:12950664-Drug Combinations, pubmed-meshheading:12950664-Drug Resistance, pubmed-meshheading:12950664-Drug Therapy, Combination, pubmed-meshheading:12950664-Female, pubmed-meshheading:12950664-Humans, pubmed-meshheading:12950664-Infant, pubmed-meshheading:12950664-Malaria, Falciparum, pubmed-meshheading:12950664-Male, pubmed-meshheading:12950664-Nigeria, pubmed-meshheading:12950664-Parasitemia, pubmed-meshheading:12950664-Plasmodium falciparum, pubmed-meshheading:12950664-Pyrimethamine, pubmed-meshheading:12950664-Sulfadoxine
pubmed:year
2003
pubmed:articleTitle
Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs.
pubmed:affiliation
Department of Pharmacology & Therapeutics, University of Ibadan, Ibadan, Nigeria. malaria.iba@alpha.linkserve.com
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't